Paraneoplastic cerebellar degeneration …

Neuro-Oncology

Updated 05.28.2024
Released 02.22.1994
Expires For CME 05.28.2027

Paraneoplastic cerebellar degeneration

Authors: Shailee Shah MD MS, Shameer Rafee MRCPI

See Contributor Disclosures

Editor: Rimas V Lukas MD

Paraneoplastic cerebellar degeneration

In This Article

Quick Link

Introduction

Overview

Paraneoplastic neurologic syndromes are characterized by a diverse array of phenotypic neurologic manifestations associated with an underlying malignancy. Paraneoplastic cerebellar degeneration is an uncommon but often devastating complication of malignancy in adults. The syndrome, which has been reclassified in the updated 2021 paraneoplastic neurologic syndromes criteria as rapidly progressive cerebellar syndrome, manifests as an acute or subacute onset of ataxia, vertigo, or oscillopsia (29). The syndrome is often associated with occult small cell lung cancer, gynecologic cancers, breast cancer, and lymphoma. The immunopathogenesis of neuronal injury in paraneoplastic cerebellar degeneration is poorly understood but is thought to be related to antibody and cytotoxic T-cell mediated immune responses. Some patients have defined circulating autoantibodies, but often no underlying antibody is identified. Specific antibodies have phenotypic associations and can guide investigations. The authors review the clinical features, autoimmune aspects, and practical management of this important condition.

Key points

	• Paraneoplastic cerebellar degeneration, or rapidly progressive cerebellar syndrome, can be classified as paraneoplastic based on association with cancer or presence of autoantibody with a high pretest probability of cancer greater than 70%.
	• Paraneoplastic cerebellar degeneration may present as an isolated subacute pancerebellar syndrome or as part of a multifocal neurologic disorder and is most commonly seen in association with breast cancer, small cell lung cancer, and lymphoma.
	• In patients with paraneoplastic cerebellar degeneration, circulating autoantibodies, when present, can guide the search for an underlying neoplasm and provide insight into outcomes.
	• Two well-recognized autoantibodies associated with paraneoplastic cerebellar degeneration include Purkinje cell cytoplasmic antibody 1 (PCA1, or anti-Yo) associated with breast and ovarian cancer and Purkinje cell cytoplasmic antibody Tr (anti-Tr or anti-delta/notch-like epidermal growth factor-related receptor [DNER]) associated with lymphoma. Paraneoplastic cerebellar degeneration can also be seen with anti-Hu (ANNA-1) antibody, which is often associated with small cell lung cancer. These and other antibodies are often associated with symptomatic involvement of multiple components of the nervous system.
	• Paraneoplastic cerebellar degeneration can be a disabling condition, and patients may not have significant neurologic improvement despite therapy combining both immunosuppressive therapies and cancer treatment when present.

Historical note and terminology

The occurrence of subacute cerebellar degeneration in patients with systemic cancer was noted more than 60 years ago (58). Subsequently, an etiologic association between cancer and cerebellar degeneration was first clearly postulated by Lord Russell Brain in 1951 (07).

Clinical manifestations

Presentation and course

Patients with paraneoplastic cerebellar degeneration present with symptoms suggestive of a pancerebellar syndrome. They typically present with acute onset dizziness, incoordination, and gait instability over weeks and will develop progressive appendicular and truncal ataxia, sometimes with brainstem involvement such as oscillopsia, dysarthria, dysphagia, and dysphonia. Abnormalities of oculomotor function are common and include nystagmus (particularly downbeat nystagmus), disruption of smooth pursuit movements, ocular dysmetria, and opsoclonus. PCA1 (anti-Yo), PCA-Tr (anti-Tr or anti-delta/notch-like epidermal growth factor-related receptor [DNER]), and mGluR1 (metabotroptic glutamate receptor 1) IgG are principally associated with a cerebellar syndrome whereas the other paraneoplastic autoantibodies (such as anti-Hu [ANNA-1]) may manifest with multilevel neuroaxis involvement such as the peripheral nerve or dorsal root ganglia (56).

One large case series noted a mean age at onset of 46 years, with the majority of patients presenting with subacute (2 weeks to 3 months) disease onset. Gait ataxia, followed by limb ataxia, dizziness, dysarthria/dysphagia, nystagmus, and double vision, were the most common presenting symptoms; 28% of patients also had pyramidal signs, and 15% had radiculopathy/peripheral neuropathy. Prodromal symptoms like cough, fever, and diarrhea are also commonly reported (46).

Patients with antineuronal nuclear autoantibody type 1 (ANNA1 or anti-Hu) antibodies are more likely to have multilevel neurosis involvement such as encephalopathy, brainstem syndrome, myelopathy, sensory neuronopathy, neuropathy, and even disorders of the neuromuscular junction. In these instances, multiple antibodies indicating neurologic autoimmunity may be found concomitantly. Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration may coexist when P/Q type calcium channel (PQ VGCC) antibodies are present (59; 52). Antineuronal nuclear autoantibody type 2 (ANNA-2) may also present with paraneoplastic cerebellar degeneration in the context of other brainstem manifestations.

Particularly emphasis should be placed on the PCA1 antibodies. PCA1 antibodies are almost entirely restricted to patients with paraneoplastic cerebellar degeneration and carcinomas of the breast (importantly in both men and women), ovary, endometrium, and fallopian tubes (38; 56). There are a few reported women and men with other adenocarcinomas (53). A small percentage of patients have been identified with breast or ovarian cancer but no neurologic symptoms (17).

Antiglial nuclear antibody (AGNA) are now referred to as anti-SOX1 due to their targeting of the SOX1 protein. There is a strong link with lung cancer, Lambert-Eaton myasthenic syndrome (LEMS), and cerebellar ataxia. Although LEMS and cerebellar ataxia are the most common phenotypes, limbic encephalitis, encephalomyelitis, and gastrointestinal pseudo-obstruction have also been reported. Cell-based assays are the most sensitive diagnostic test (79). SOX1 is part of a large family of developmental transcription factors and are highly expressed in the early neuroectoderm and nervous system. It was first noted to be antigenic in LEMS in 2005 (65).

Anti-kelch-like protein 11 antibody disease manifestations include hearing disorders and cognitive changes and rarely opsoclonus-myoclonus, long spinal cord lesions, dysarthria, and seizures. Cerebellar atrophy is commonly noted on imaging, and most patients have an inflammatory CSF (45).

Neurologic symptoms often precede the diagnosis of malignancy, antedating the discovery by up to 2 years (59). In patients with PCA-Tr antibodies and Hodgkin lymphoma, initial reports demonstrated that disease onset appeared to occur after Hodgkin diagnosis, but other reports suggest up to 80% of patients may have symptoms prior to cancer diagnosis (06; 70).

Prognosis and complications

Neurologic deficits in paraneoplastic cerebellar degeneration generally worsen over a period of several weeks to months and then stabilize frequently with disability. Only about one third of patients can walk independently, and many patients cannot sit up or feed themselves. With few exceptions, paraneoplastic cerebellar degeneration does not remit spontaneously (39). Younger patients, with less disability, and early-stage malignancy treated early and aggressively from an immunologic and oncologic perspective experience better neurologic outcomes and longer survival (06). An overall mortality of around 10% has been described (46). These somewhat favorable results in patients with malignancy, severe irreversible neurologic deficits, and poor performance status may reflect a limited duration of follow-up and attrition of patients from the study.

Survival varies with antibody type and may be worse in patients with ANNA1, PCA1 compared to those with ANNA2 or PCA-Tr antibodies (39; 52; 70; 39). Survival outcomes are, of course, impacted by duration of follow-up (ie, shorter study follow-up, better survival). Significant neurologic improvement after successful treatment of the associated tumor appears to be more common in patients with ANNA-2, Collapsin response mediator protein 5 (CRMP-5) antibodies, and PCA-Tr antibodies. Although exceptions exist, patients with antibodies against plasma membrane antigenic targets such as mGluR1, acetylcholine receptor antibodies, voltage gated calcium channel (VGCC) antibodies, and PCA-Tr antibodies generally appear to have better outcomes than those with autoantibodies that target nuclear or cytoplasmic antigens.

Clinical vignette

A previously healthy 57-year-old woman acutely developed vertigo, nausea and vomiting, intermittent diplopia, and unsteady gait. Over the next several weeks, the symptoms persisted, and she also developed slurred speech and incoordination of both hands. Examination 2 months later was notable for the following: coarse right-beating nystagmus in primary gaze (worse looking to the right), mild weakness of the right lower face, moderate dysarthria, exaggerated gag reflex, titubation of the head and trunk, dysmetria and intention tremor of both upper extremities, and diffuse hyperreflexia with a Babinski sign on the right. She was unable to stand without assistance and could not walk. Brain MR scan was unremarkable. CSF was notable for 60 nucleated cells, lymphocytic predominate, protein 96 mg/dl, IgG 19.3 mg/dl (upper limit 6.0), elevated IgG index, and three unique CSF oligoclonal bands. Chest x-ray was normal as was CT of the chest, abdomen, and pelvis. Serum and CSF contained high-titer anti-PCA1 ("anti-Yo") antibodies. Mammogram (which the patient never previously had) showed left-sided mass and biopsy demonstrated adenocarcinoma.

The patient was administered 5 days of intravenous methylprednisolone and 5 days of intravenous immunoglobulin 0.4 mg/kg daily with plans for repeated infusions of methylprednisolone on a weekly basis for 12 weeks. She was referred to oncology. Two axillary lymph nodes were positive for tumor, and she was begun on chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil. The cyclophosphamide served a dual purpose of treating both the immunologic disease and oncologic disease. Approximately 3 months later, the neurologic exam had stabilized. The weekly infusions were increased to twice weekly and then gradually weaned off. Plasmapheresis was offered, but she declined and was transferred to a chronic care facility. Six months later (after four cycles of chemotherapy), no tumor was evident. Her neurologic deficits had improved slightly but she remained nonambulatory. Repeated MRI of the brain at this time demonstrated cerebellar hemispheric and vermian atrophy.

Biological basis

Etiology and pathogenesis

Autoantibodies. Patients with paraneoplastic and nonparaneoplastic autoimmune cerebellar degeneration have one of a steadily growing number of antineuronal autoantibodies identified in serum and CSF (Table 1) (39). To date, virtually all known paraneoplastic antibodies react with cerebellar neural antigens. Antibodies targeting both intracellular and cell surface (or plasma membrane) proteins have been identified to be associated with cerebellar degeneration, with and without an associated malignancy. mGluR1 antibodies, VGCC antibodies, and PCA-Tr antibodies are directed against antigens located on the cell surface in contrast to the great majority of antineuronal antibodies whose antigenic targets are intracellular including PCA1, ANNA1, and CRMP5 antibodies. GAD65 antibodies were one of the first to be discovered and have a varied presentation, including cerebellar ataxia phenotype (43%), but overlap syndromes are common. The incidence of malignancies are rare (4%) (08).

Rarer novel autoantibodies continue to be identified. One such autoantibody is plasticity-related gene 5 (PRG5) associated with squamous cell cancer of the lung and tripartite motif-containing protein 9, 46, and 67 (TRIM9/TRIM46/TRIM67) with pulmonary adenocarcinoma and carbonic anhydrase-related protein VII (CARPVII) and breast adenocarcinoma (80; 81; 16; 62). Metabotropic glutamate receptor 2 antibody (mGluR2-Ab) has also been described in patients presenting with various underlying cancers (64). Antibodies to glucose-regulated protein 78 (GRP78) were identified to alter and facilitate the brain uptake of autoantibodies across the blood-brain barrier, causing paraneoplastic cerebellar degeneration (71). Seizure-related 6 homolog like 2 antibodies (SEZ6L2-abs) described in four patients presents with subacute gait ataxia and extrapyramidal syndromes (44). Another autoantibody is GTPase regulator associated with focal adhesion kinase 1/Rho GTPase activating protein 26‐immunoglobulin (GRAF1/ARHGAP26‐IgG), of which there are 27 cases reported in which the patients present with progressive cerebellar syndrome and more rarely peripheral neuropathy (60). The list of autoantibodies continues to expand and include antibodies targeting proteins: HOMER-3, GluK2, AP3B2, Septin-3 and 5, GluRδ2, PKCy, RGS8, and mGLUR5 (69).

Another newly described autoantibody, kelch-like protein 11 (KLH11), is associated with a brainstem encephalitis and less commonly a progressive cerebellar syndrome. It is associated with testicular and less commonly extratesticular germ cell tumors and in a subset of patients only a regressed germ cell tumor is identified (49; 19).

Table 1. Common Autoantibodies in Paraneoplastic Cerebellar Degeneration

Antineuronal antibody	Associated tumors	Antigen
PCA1 (anti-Yo)-IgG	breast, ovarian carcinoma, mullerian adenocarcinoma	Purkinje cell cytoplasm and dendrites; 55 kd cdr2L protein
ANNA1 (anti-Hu)-IgG	small cell lung carcinoma	pan-neuronal nuclei greater than cytoplasm; 35 to 40 kd RNA-binding protein – embryonic lethal abnormal visio-like (ELAVL) or Hu (HuD primarily)
Anti-glial nuclear antibody (AGNA or anti-SOX1 SRY-like high mobility group box)–IgG	small cell lung carcinoma	SOX1 transcription factor; specifically, the DNA binding domain high mobility group (HMG) – box
CRMP-5 (anti-CV2)-IgG	small cell lung carcinoma, thymoma, others	cytoplasm of neurons and oligodendrocytes, peripheral nerve axons; 62 kd CRMP-5 protein
Amphiphysin-IgG	small cell lung carcinoma	neuropil; 128 kd synaptic vesicle-associated amphiphysin
P/Q-type VGCC-IgG	small cell lung carcinoma	voltage-gated calcium channels
PCA2-IgG	small cell lung carcinoma	cytoplasm of Purkinje cells, neurons in granular layer and dentate nuclei; 280 kd microtubule-associated protein 1B
ANNA3-IgG	small cell lung carcinoma	Purkinje cell and dentate neuronal nuclei; unknown 170 kd protein
ANNA2 (anti-Ri)-IgG	breast, lung carcinoma	pan-neuronal nuclei greater than cytoplasm; 53 to 61 kd and 79 to 84 kd RNA-binding proteins (NOVA1 and NOVA2)
Ma1/Ma2-IgG	Lung adenocarcinoma, testicular tumors	panneuronal nuclei and nucleoli; 40 to 42 kd Ma1 and Ma2 proteins
PCA-Tr-IgG	Hodgkin lymphoma	Purkinje cell cytoplasm and dendritic trees, punctate staining in molecular layer; Delta/Notch-like epidermal growth factor-related receptor
mGluR1-IgG	lymphoma, prostate carcinoma, seminoma	metabotropic glutamate receptor
GAD65-IgG	pancreatic, lymphoma, thymic tumors, others	65 kd glutamic acid decarboxylase
GABA-B receptor-IgG	Small-cell lung cancer; melanoma	Extracellular domain of B1 subunit of GABA-B receptor
Neuronal intermediate filament (NIF)-IgG (03)	Small-cell lung cancer; Merkel cell carcinoma	Cytoplasmic neuronal intermediate filaments (αIN, NfL, NfM, and NfH)
Kelch-like protein 11 (KLH11)-IgG	Germ cell tumors (seminomas); lung adenocarcinoma	Ketch-like protein 11, member of the E3 ubiquitin-protein ligase complex

The pathogenesis of several of these autoantibodies is discussed in greater detail below.

PCA1. PCA1 antibodies were one of the first described paraneoplastic autoantibodies (38) and characteristically stain the cytoplasm and proximal dendrites of Purkinje cells in a coarsely clumped pattern by immunochemistry.

Paraneoplastic cerebellar degeneration (photomicrograph)

Photomicrograph of normal human cerebellar cortex stained with serum from a patient with breast carcinoma, paraneoplastic cerebellar degeneration, and anti-Yo antibodies. The indirect immunoperoxidase technique yields characterist...

PCA1 antibodies react specifically with a 58 to 62 kd protein and (less strongly and consistently) with a 34 to 38 kd protein (12; 18; 75).

Initially, several target autoantigens for PCA1 antibodies were cloned using serum from affected patients as antibody probes to screen human cDNA expression libraries (18; 21). Three of the cloned autoantigens (PCD17, CDR62, and CDR3) share a high degree of sequence homology with one another and feature a "leucine zipper". CDR62 (or CDR2) downregulates c-Myc-dependent transcription and suppresses transcriptional activity dependent on nuclear factor-kappa B (57) and antibody reactivity to some but not all breast and ovarian cancers has been seen providing mechanistic insights (21; 68). Initially, the primary antigen was thought to be CDR2 but work has demonstrated that CDR2L is the major antigenic target for these antibodies (43; 33). Models for immune-mediated tumor regression in mice have defined the essential role of cytotoxic T lymphocytes in tumor immunity and autoimmune neuronal degeneration (02). Investigations have elucidated a potential association with several HLA class 2 alleles (34), suggesting a potential background of autoimmunity in patients with PCA1 antibodies.

PCA-Tr. PCA-Tr in association with cerebellar degeneration is the most common phenotype associated with Hodgkin lymphoma, and less commonly with non-Hodgkin lymphoma (06; 24). The antigenic target of anti-Tr antibodies has been identified as the Delta/Notch-like epidermal growth factor-related receptor (15; 30). Sera of patients with anti-Tr applied to tissue show a characteristic immunostaining pattern of punctate reactivity in the soma and large dendrites of Purkinje cells, and some neurons in the molecular layer (26). Detection of these antibodies is thought to be more often seen in the CSF than serum (06).

mGluR1. mGluR1 autoantibodies appear to cause a pancerebellar syndrome that is subacute and can be associated with the unique syndrome of dysgeusia (47). Autoantibodies were first detected in two patients in the early 2000s to these g-protein coupled cell surface receptors (72). There is a distinct Purkinje-cell body staining that is punctate and compatible with Purkinje cell spines observed in the molecular layer of the cerebellum; staining of neuron of the olfactory bulbe, tubercle, cerebral cortex, CA3 hippocampal region, thalamus, superior colliculus, and spinal trigeminal nucleus. In vitro application of patients' IgG to mouse cerebellar slices blocks mGluR1-mediated currents, and in vivo infusion of patients' IgG into mouse cerebellum causes abnormal eye movements (11).

Pathogenesis. The most striking and consistent neuropathologic finding in paraneoplastic cerebellar degeneration is a severe, diffuse loss of Purkinje cells throughout the cerebellar cortex. In extreme cases, an almost complete disappearance of Purkinje cells takes place. The remaining Purkinje cells often show nonspecific degenerative changes and are surrounded by a reactive proliferation of Bergmann astroglial cells (83; 52; 74). There may also be some neuronal loss in the granular cell layer and deep cerebellar nuclei. Some patients have perivascular cuffing and mononuclear cell infiltrates in the cerebellum and overlying leptomeninges. Up to one half of autopsied patients with predominant cerebellar signs and symptoms have a multifocal encephalomyelitis, with patchy neuronal loss and inflammatory infiltrates scattered through the cerebral hemispheres, brainstem, and spinal cord (56).

The central theory of autoimmune or paraneoplastic neurologic disorders is that an individual's tumor cells express antigenically identical or related to molecules normally expressed by neurons. In rare instances, an autoimmune response initially arising against "onconeural" antigens expressed by tumor cells subsequently attacks neurons expressing the same or related antigens (13). Clear pathogenicity of most autoantibodies has not been established but is instead considered biomarkers of neurologic autoimmunity.

Intraventricular injection of patients' PCA1 sera into rodents results in uptake of human IgG into the cytoplasm of Purkinje cells and other cerebellar neurons, without causing any notable clinical effects or neuropathologic changes (27; 76). In a study, patient PCA1 antibodies applied to cerebellar slice cultures were taken up by Purkinje cells and were associated with Purkinje cell death (31). Mice immunized with recombinant PCD17 protein produce high-titer anti-Yo antibodies but do not develop the clinical or pathological features of cerebellar degeneration (67; 76). Injection of peripheral mononuclear cells from patients with paraneoplastic cerebellar degeneration into mice with severe combined immunodeficiency results in the production of low titers of anti-Purkinje cell antibodies, but with no clinical or neuropathologic changes (76). Similarly, animals actively immunized with recombinant Hu proteins (73) or with HuD DNA vaccination (09) produce anti-Hu antibodies but do not develop clinical disease. By contrast, intrathecal injection of sera from patients with cell surface protein targeting voltage-gated calcium channel IgG into mice causes reversible ataxia (51).

Cytotoxic T cell responses have been thought to be critical to the development of neurologic disease (02; 01). It is postulated that onconeural antigens released by apoptotic tumor cells are presented to T lymphocytes in draining peripheral lymph nodes, initiating a Th1 helper response that eventually gains access to the CNS and attacks neurons expressing the antigens but mechanisms for these are largely unknown. Patients with paraneoplastic cerebellar degeneration and PCA1 antibodies have activated T lymphocytes in the cerebrospinal fluid (01). At autopsy, some patients with PCA1 antibodies have parenchymal and perivascular infiltration of CD8+ T-lymphocytes in the cerebellum and other areas of the brain (56). Some studies identified circulating CD8+ cytotoxic T lymphocytes reacting with HuD protein (77; 63).

Differential diagnosis

Paraneoplastic cerebellar degeneration should be considered in any adult presenting with subacute pancerebellar dysfunction (25). Often, it can be distinguished from degenerative conditions by its abrupt onset and rapid progression to severe disability over several weeks to months, but this is not always the case. The differential diagnosis of diffuse cerebellar dysfunction in adults includes inherited or sporadic neurodegenerative disorders such as the olivopontocerebellar atrophies, spinocerebellar degeneration, or multiple system atrophy (42). Rarer diseases including prion disorders such as Creutzfeldt-Jakob disease or Gerstmann-Sträussler-Scheinker can present with primarily a cerebellar degeneration. Toxic or metabolic conditions that cause cerebellar syndromes include medication use, heavy metal poisoning, thyroid dysfunction, vitamin deficiency or alcoholism, HIV, and gluten-related or celiac disease. Therapy with phenytoin, 5-fluorouracil, and/or high-dose intravenous cytarabine treatment can present with cerebellar dysfunction; the incidence of these toxicities often increases with cumulative dose of the drug and increasing patient's age.

Demyelinating disease, cerebrovascular disease, neoplasm, infectious or postinfectious cerebellitis, or Miller-Fisher variant of Guillain-Barre syndrome can also occur.

Several autoantibodies, particularly those targeted against plasma-membrane proteins, are associated with autoimmune ataxia but without an underlying malignancy. Some may still be classified as paraneoplastic given their high predictive value for specific cancers, for example, PCA-Tr and Hodgkin lymphoma.

Several autoantibodies targeting GAD65, PCA-Tr, P/Q type VGCC, CASPR2, GABA-B, and mGLUR1 occur without an identified neoplastic association (37). GAD65 ataxia is notable in that it is associated with intracellular GAD65 autoantibodies but is not commonly associated with malignancy except thymoma in 10% of cases (66; 50; 05). Syndromically, it may occur with other forms of nonneurologic autoimmunity such as type 1 diabetes, autoimmune thyroiditis, and pernicious anemia.

Confusing conditions

The differential diagnosis of paraneoplastic cerebellar degeneration includes structural lesions such as brain metastasis, neurodegenerative conditions (multiple system atrophy, Creutzfeldt-Jakob disease), and toxic-metabolic derangements (medication related or iatrogenic, vitamin deficiencies, hypothyroidism, alcoholism, HIV, celiac disease). Demyelinating disease, cerebrovascular disease, and peri- or post-infectious causes can also be considered.

Diagnostic workup

Laboratory testing for alternative causes of cerebellar ataxia should be pursued and careful family history should be taken. Testing may include basic chemistry panels, thyroid function, antinuclear antibodies and celiac testing, and HIV and GAD antibodies.

Brain MRI may be normal-appearing initially. It can be used to exclude alternative etiologies. Rarely, in the acute phases, MRI may show cerebellar T2 signal abnormalities or contrast enhancement of the cerebellar folia (14; 23). Fluorodeoxyglucose-PET brain scanning may show diffuse cerebellar hypermetabolism in the acute phase as well (10). In chronic stages diffuse cerebellar atrophy can be seen (59).

Basic cerebrospinal fluid studies can be relatively nonspecific or normal but in approximately one half of patients with paraneoplastic cerebellar degeneration shows slightly elevated protein or a mild lymphocytic pleocytosis (10-50 lymphocytic cells), elevated IgG index, and CSF specific oligoclonal bands (59).

We recommend autoantibody testing in both CSF and serum in patients in whom there is a strong clinical suspicion of neurologic autoimmunity. Not all antibodies are commercially available or well characterized and so if clinical suspicion is present, testing on a research basis may be warranted. Due to these limitations, an autoantibody may not be identified in a case of autoimmune or paraneoplastic cerebellar degeneration (20).

Some notes should be made regarding antibody associations and titers. No clear association exists between antibody titers and tumor development (06; 70; 15). Some patients with breast, ovarian, and small cell lung cancers have been found to have low titers of antineuronal antibodies without neurologic autoimmunity (17; 04). Additionally, when GAD65 or acetylcholine receptor antibodies are detected in serum, lower titers may have no clear association with malignancy or neurologic autoimmunity.

Investigation for occult malignancy should ensue in patients without a cancer diagnosis. The level of suspicion for specific malignancy diagnosis should be determined based on patient age, gender, tobacco abuse history, family history, and importantly, the paraneoplastic autoantibody specificity. We generally recommend patients undergo a CT of the chest abdomen and pelvis and/or PET scan of the body, particularly when the associated autoantibody has a high pretest probability of cancer (32; 55; 54). Mammogram and pelvic ultrasound should be considered in women if not recently performed (78). Empirical chemotherapy or other antitumor treatment without histologic proof of cancer is not recommended. In women with PCA1 antibodies, if mammogram and pelvic ultrasound are unrevealing, further testing such as breast MRI or CA125 testing with interval screening may be warranted due to the high association with these malignancies in these patients.

Comments regarding specific autoantibodies and their association with small cell lung cancer should be made. ANNA1 and CRMP5 autoantibodies are the most well recognized syndrome associations. Additionally, patients with small cell lung cancer and paraneoplastic cerebellar degeneration (or other neurologic syndrome) may have more than one type of circulating antineuronal antibody, often at lower titers (04; 61; 35; 36). The co-occurrence of antibodies may also indicate neurologic involvement at multiple levels of the nervous system. Autoantibodies to SOX1 or VGCC predict small cell lung cancer in patients with cerebellar degeneration or Lambert-Eaton myasthenic syndrome (48).

Management

Systematic analysis of immunologic and oncologic treatment in the management of these patients has been hampered by the rarity of the disease and recommendations are primarily derived from retrospective literature. Oncologic therapy is generally accepted to be necessary for disease stabilization or improvement and should be pursued expeditiously.

Immunotherapy is often utilized but it remains unclear to what degree (and in what direction---favorable or unfavorable) it impacts disease course. Historically, outcomes for patients with paraneoplastic cerebellar degeneration have been poor despite immunologic or oncologic therapy and the majority remaining nonambulatory at last follow-up. However, some anecdotal reports and retrospective series have reported improvements with plasma exchange, intravenous immunoglobulin, corticosteroids, and longer term immunosuppressants such as cyclophosphamide and rituximab. As compared to those with nonparaneoplastic (autoimmune) ataxias, immunotherapy responsiveness differs and improvement to ambulatory status is only seen in approximately 30% of patients (39).

The poor clinical response to corticosteroids or plasma exchange does not necessarily refute an autoimmune pathogenesis, as it is likely that by the time paraneoplastic cerebellar degeneration is diagnosed, many patients have already suffered irreversible neuronal damage or loss (22).

Given the disabling nature of these syndromes and uncertainty of the diagnosis at initial encounters, it is reasonable to attempt an early and aggressive immunotherapy trial, with objective measures taken pre- and post-treatment to assess for improvement. Prior literature has suggested that early immunotherapy may be associated with better outcomes (85; 39). Acute immunotherapies such as intravenous steroids, plasmapheresis, and intravenous immunoglobulin can be considered and can be continued on a weekly basis for up 6 to 12 weeks to provide ample time to assess adequate response. Longer term, aggressive immunotherapy such as rituximab or oral or intravenous cyclophosphamide can be considered (41; 28; 70; 56; 39).

References

01: Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000;47:9-17. PMID 10632096
02: Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998;4(11):1321-4. PMID 9809559
03: Basal E, Zalewski N, Kryzer TJ, et al. Paraneoplastic neuronal intermediate filament autoimmunity. Neurology 2018;91(18):e1677-89. PMID 30282771
04: Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurological disorders and small cell lung cancer. Neurology 2004a;62:778-782. PMID 15007130
05: Becker EB, Zuliani L, Pettingil R, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatr 2012;83(4):437-40. PMID 22338029
06: Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003;60:230-4. PMID 12552036
07: Brain WR, Daniel PM, Greenfield JG. Subacute cortical cerebellar degeneration and its relation to carcinoma. J Neurol Neurosurg Psychiatry 1951;14:59-75. PMID 14850992
08: Budhram A, Sechi E, Flanagan EP, et al. Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry 2021;92(6):645-54. PMID 33563803
09: Carpentier AF, Rosenfeld MR, Delattre JY, et al. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998;4:2819-24. PMID 9829748
10: Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatr 2006;77:525-8. PMID 16543536
11: Coesmans M, Sillevis Smitt PA, Linden DJ, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003;53:325-36. PMID 12601700
12: Cunningham J, Graus F, Anderson NE, Posner JB. Partial characterization of Purkinje cell antigens in paraneoplastic cerebellar degeneration. Neurology 1986;36:1163-8. PMID 3528917
13: Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7(4):327-40. PMID 18339348
14: de Andres C, Esquivel A, de Villoria JG, Graus F, Sanchez-Ramon S. Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. J Neurol Neurosurg Psychiatry 2006;77(4):562-3. PMID 16543544
15: de Graaff E, Maat P, Hulsenboom E, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012;71(6):815-24. PMID 22447725
16: Do LD, Gupton SL, Tanji K, et al. TRIM9 and TRIM67 are new targets in paraneoplastic cerebellar degeneration. Cerebellum 2019;18(2):245-54. PMID 30350014
17: Drlicek M, Bianchi G, Boglium G, et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 1997;244:85-9. PMID 9120501
18: Dropcho EJ, Chen YT, Posner JB, Old LJ. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A 1987;84:4552-6. PMID 3474619
19: Dubey D, Wilson MR, Clarkson B, et al. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis. JAMA Neurol 2020;77(11):1420-9. PMID 32744608
20: Ducray F, Demarquay G, Graus F, et al. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. Eur J Neurol 2014;21(5):731-5. PMID 24871811
21: Fathallah-Shaykh H, Wolf S, Wong E, Posner JB, Furneaux H. Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A 1991;88:3451-4. PMID 2014264
22: Furneaux HM, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990;40(7):1085-91. PMID 2356009
23: Gilmore CP, Elliott I, Auer D, Maddison P. Diffuse cerebellar MR imaging changes in anti-Yo positive paraneoplastic cerebellar degeneration. J Neurol 2010;257(3):490-1. PMID 19943166
24: Graus F, Arino H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014;123:3230-8. PMID 24705493
25: Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neuro Neurosurg Psychiatry 2004;75(8):1135-40. PMID 15258215
26: Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin’s disease in the rat nervous system. Acta Neuropathol 1998;96:1-7. PMID 9678507
27: Graus F, Illa I, Agusti M, et al. Effect of intraventricular injection of anti-Purkinje cell antibodies (anti-Yo) in a guinea pig model. J Neurol Sci 1991;106:82-7. PMID 1779243
28: Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-48. PMID 11353730
29: Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021;8(4):e1014. PMID 34006622
30: Greene M, Lai Y, Baella N, Dalmau J, Lancaster E. Antibodies to Delta/Notch-like epidermal growth factor-related receptor in patients with anti-Tr paraneoplastic cerebellar degeneration and Hodgkin lymphoma. JAMA Neurol 2014;71:1003-8. PMID 24935874
31: Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol 2010b;69(10):997-1007. PMID 20838245
32: Hadjivassiliou M, Alder SJ, Van Beek EJ, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand 2009;119(3):186-93. PMID 18855873
33: Herdlevaer I, Kråkenes T, Schubert M, Vedeler CA. Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration. Ann Clin Transl Neurol 2020;7(11):2231-42. PMID 33009713
34: Hillary RP, Ollila HM, Lin L, et al. Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. J Neuroimmunol 2018;315:28-32. PMID 29306402
35: Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological syndromes in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80(4):412-6. PMID 18931014
36: Horta ES, Lennon VA, Lachance DH, et al. Neural autoantibody clusters aid diagnosis of cancer. Clin Cancer Res 2014;20:3862-9. PMID 24833664
37: Ito H, Sayama S, Irie S, et al. Antineuronal antibodies in acute cerebellar ataxia following Epstein-Barr virus infection. Neurology 1994;44:1506-7. PMID 8058157
38: Jaeckle KA, Graus F, Houghton AN, et al. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol 1985;18:592-600. PMID 2416270
39: Jones AL, Flanagan EP, Pittock SJ, et al. Responses and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol 2015;72:1304-12. PMID 26414229
40: Kawamura R, Nagata E, Mukai M, et al. Acute cerebellar ataxia induced by nivolumab. Intern Med 2017;56(24):3357-9. PMID 29249765
41: Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000;68:479-82. PMID 10727484
42: Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol 2010;9(1):94-104. PMID 20083040
43: Krakenes T, Herdlevaer I, Raspotnig M, Haugen M, Schubert M, Vedeler CA. CDR2L is the major yo antibody target in paraneoplastic cerebellar degeneration. Ann Neurol 2019;86(2):316-21. PMID 31148214
44: Landa J, Guasp M, Petit-Pedrol M, et al. Seizure-related 6 homolog like 2 autoimmunity: neurologic syndrome and antibody effects. Neurol Neuroimmunol Neuroinflamm 2020;8(1):e916. PMID 33144342
45: Leon Betancourt A, Schwarzwald A, Millonig A, et al. Anti-kelchlike protein 11 antibody-associated encephalitis: two case reports and review of the literature. Eur J Neurol 2023. PMID 36815561
46: Liu M, Ren H, Zhu Y, et al. Autoimmune cerebellar ataxia: etiology and clinical characteristics of a case series from China. Cerebellum 2023. PMID 35618871
47: Lopez-Chiriboga AS, Komorowski L, Kümpfel T, et al. Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology 2016;86(11):1009-13. PMID 26888994
48: Maddison P, Titulaer MJ, Verschuuren JJ, et al. The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. J Neuroimmunol 2019;326:14-8. PMID 30445363
49: Mandel-Brehm C, Dubey D, Kryzer TJ, et al. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 2019;381(1):47-54. PMID 31269365
50: Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease. Arch Neurol 2010;67(5):627-30. PMID 20457964
51: Martin-Garcia E, Mannara F, Gutierrez-Cuestra J, et al. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013;261(1-2):53-9. PMID 23726906
52: Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997;120:1279-300. PMID 9278623
53: Matschke J, Kromminga A, Erbersdobler A, Lamszus K, Anders S, Kofuncu E. Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma. J Neurol Neurosurg Psychiatr 2007;78:775-7. PMID 17189300
54: Matsuhisa A, Toriihara A, Kubota K, Makino T, Mizusawa H, Shibuya H. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes. Clin Nucl Med 2012;37(1):39-43. PMID 22157026
55: McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systemic analysis and review. Arch Neurol 2010;67(3):322-9. PMID 20065123
56: McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol 2011;68(10):1282-9. PMID 21670387
57: O'Donovan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB. The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells. PLoS One 2010;5(4):e10045. PMID 20383333
58: Parker HL, Kernohan JW. Parenchymatous cortical cerebellar atrophy (chronic atrophy of Purkinje's cells). Brain 1933;56:191-212.
59: Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration: a clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931-7. PMID 1407575
60: Pittock SJ, Alfugham N, O'Connor K, et al. GTPase regulator associated with focal adhesion kinase 1 (GRAF1) immunoglobulin-associated ataxia and neuropathy. Mov Disord Clin Pract 2020;7(8):904-9. PMID 33163561
61: Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-9. PMID 15468074
62: Prevezianou A, Tzartos JS, Dagklis IE, et al. Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies. J Neuroimmunol 2020;344:577242. PMID 32325285
63: Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009;119(7):2042-51. PMID 19509467
64: Ruiz-García R, Martínez-Hernández E, Joubert B, et al. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol Neuroimmunol Neuroinflamm 2019;7(2):e658. PMID 31826987
65: Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert–Eaton myasthenic syndrome. Neurology 2008;70(12):924-8. PMID 18032743
66: Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008;131(Pt 10):2553-63. PMID 18687732
67: Sakai K, Gofuku M, Kitagawa Y, Ogasawara T, Hirose G. Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein. J Neuroimmunol 1995;60:135-41. PMID 7642741
68: Sakai K, Ogasawara T, Hirose G, et al. Analysis of autoantibody binding to 52-kd paraneoplastic cerebellar degeneration-associated antigen expressed in recombinant proteins. Ann Neurol 1993;33:373-80. PMID 8489208
69: Segal Y, Zekeridou A. Interest of rare autoantibodies in autoimmune encephalitis and paraneoplastic neurological syndromes: the utility (or futility) of rare antibody discovery. Curr Opin Neurol 2024;37(3):295-304. PMID 38533672
70: Shams’ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409-18. PMID 12764061
71: Shimizu F, Takeshita Y, Sano Y, et al. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain 2019;142(8):2253-64. PMID 31236596
72: Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. New Engl J Med 2000;342:21-7. PMID 10620645
73: Sillevis Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995;45:1873-8. PMID 7477985
74: Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand 2009;120(1):64-7. PMID 19486326
75: Tanaka K, Tanaka M, Tsukamoto T, Uehara T, Tsuji S. Anti-Yo antibody binding to 62-, 52-, or 58-kd protein recognizes a single molecule. Neurology 1996;46:1777-8. PMID 8649596
76: Tanaka M, Tanaka K, Igarashi S, et al. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody: II. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg 1995a;97:101-5. PMID 7788964
77: Tanaka M, Tanaka K, Shinozawa K, Idezuka J, Tsuji S. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1998;161:88-90. PMID 9879687
78: Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19-e3. PMID 20880069
79: Vabanesi M, Pinto AL, Vogrig A, et al. SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques. J Neurol 2023;270:1691-701. PMID 36512064
80: van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, et al. Plasticity-related gene 5: a novel surface autoantigen in paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2015;2(5):e156. PMID 26445730
81: van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, et al. Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes. Ann Clin Transl Neurol 2017;4(9):680-6. PMID 28904989
82: Velasco R, Villagrán M, Jové M, et al. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol 2021;78(7):864-73. PMID 33720308
83: Verschuuren J, Chuang L, Rosenblum MK, et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol 1996;91:519-25. PMID 8740233
84: Vogrig A, Gigli GL, Segatti S, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 2020;267(1):26-35. PMID 31552550
85: Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurooncol 2003;63:187-90. PMID 12825823
86: Zekeridou A, Lennon VA. Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc 2019;94(9):1865-78. PMID 31358366
87: Zurko J, Mehta A. Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes 2018;2(1):74-7. PMID 30225435
88: References especially recommended by the author or editor for general reading.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Shailee Shah MD MS

Dr. Shah of Vanderbilt University Medical Center has no relevant financial relationship to disclose.
See Profile
Shameer Rafee MRCPI

Dr. Rafee of University College Dublin received speaker's honorariums from Ipsen and Merz and travel grants from Abbvie and Ipsen.
See Profile

Editor

Rimas V Lukas MD

Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile

Former Authors

Edward J Dropcho MD
Daniel Lachance MD

Patient Profile

Age range of presentation: 13 to -65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Spinocerebellar disease unspecified: 334.9
ICD-10: Paraneoplastic neuromyopathy and neuropathy: G13.0
ICD-11: Paraneoplastic or autoimmune disorders of the central nervous system, brain or spinal cord: 8E4A.0

Paraneoplastic or autoimmune disorders of the peripheral or autonomic nervous system: 8E4A.1

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Paraneoplastic cerebellar degeneration

Associated Disorders

Paraneoplastic encephalomyelitis
Paraneoplastic opsoclonus-myoclonus
Lambert-Eaton myasthenic syndrome
Breast carcinoma
Ovarian carcinoma
- Bronchogenic carcinoma
- Hodgkin lymphoma

Differential Diagnosis

brain metastasis
toxic-metabolic derangements (medication related or iatrogenic, vitamin deficiencies, hypothyroidism, alcoholism, HIV, celiac disease)
demyelinating disease
cerebrovascular disease
peri- or post-infectious causes
- olivopontocerebellar atrophy
- spinocerebellar degeneration
- multiple system atrophy
- complications of high-dose cytarabine treatments
- Hashimoto autoimmune thyroiditis
- Creutzfeldt-Jakob disease
- Gerstmann-Sträussler-Scheinker syndrome
- nonparaneoplastic cerebellar degeneration
- cerebellar syndrome due to chronic phenytoin treatment
- cerebellar syndrome due to heavy-metal poisoning
- cerebellar syndrome due to chemotherapy with 5-fluorouracil
- subacute cerebellar degeneration

Also Relevant

Autoantibodies: disease markers
Lambert-Eaton myasthenic syndrome
Gait disorders
Paraneoplastic opsoclonus myoclonus syndrome in adults
Paraneoplastic sensory neuronopathy
- Paraneoplastic syndromes

Paraneoplastic cerebellar degeneration …

Paraneoplastic cerebellar degeneration

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Common Autoantibodies in Paraneoplastic Cerebellar Degeneration

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Tumors of the skull base

Multiple sclerosis: treatment of its symptoms

Anti-GQ1b antibody syndrome

Ganglioglioma

Paraneoplastic syndromes

Overview of neuropathology updates for infiltrating gliomas

Paraneoplastic cerebellar degeneration

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Common Autoantibodies in Paraneoplastic Cerebellar Degeneration

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Tumors of the skull base

Multiple sclerosis: treatment of its symptoms

Anti-GQ1b antibody syndrome

Ganglioglioma

Paraneoplastic syndromes

Overview of neuropathology updates for infiltrating gliomas

This is an article preview.
Start a Free Account
to access the full version.